Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 4/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114949 | 0.81 | CCNT1 (0.37) | CCNT1CYP11B2SCN9APDCD1CD274 | |
| SCHEMBL2114946 | 0.79 | CCNT1 (0.37) | CCNT1CYP11B2SCN9APDCD1CD274 | |
| Hydrochloric Acid SCHEMBL864992 | 0.79 | CCNT1 (0.41) | CCNT1CYP11B2SCN9APDCD1CD274 | |
| Hydrochloric Acid SCHEMBL864990 | 0.79 | CCNT1 (0.41) | CCNT1CYP11B2SCN9APDCD1CD274 | |
| Hydrochloric Acid SCHEMBL864991 | 0.79 | CCNT1 (0.41) | CCNT1CYP11B2SCN9APDCD1CD274 | |
| SCHEMBL2115279 | 0.78 | CKS1B (0.39) | PDCD1CD274TP53RBP4TTR | |
| SCHEMBL863822 | 0.71 | PIK3CD (0.42) | CCNT1BTK | |
| SCHEMBL863821 | 0.71 | PIK3CD (0.42) | CCNT1BTK | |
| SCHEMBL863823 | 0.71 | PIK3CD (0.42) | CCNT1BTK | |
| SCHEMBL864964 | 0.64 | PIM1 (0.40) | BTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | CCNT1 2033/4885CYP11B2 1248/4885SCN9A 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.